CHNQD-01281

CHNQD-01281 is a preclinical **small-molecule** anticancer candidate described as a **brefeldin A pyridine acrylate derivative** generated to improve the poor solubility, toxicity, and bioavailability profile of brefeldin A. In the cited 2024 peer-reviewed publication, the compound showed particularly strong activity against bladder cancer cell lines including T24 and J82, suppressed tumor growth in a T24 xenograft model, and prolonged survival in an MB49 allogeneic mouse model. Mechanistically, it was reported to regulate **EGFR/PI3K/AKT** and **EGFR/ERK** signaling and to promote infiltration of cytotoxic T cells, supporting development as an experimental targeted antineoplastic and immunomodulatory agent for **bladder cancer**. No INN, brand name, or clearly identified commercial developer was established from the provided public source.

Other names

CHNQD-01281CHNQD01281CHNQD 01281brefeldin A pyridine acrylate derivative